Harnessing γδ T Cells against Human Gynecologic Cancers

Immuno-oncology has traditionally focused on conventional MHC-restricted αβ T cells. Yet, unconventional γδ T cells, which kill tumor cells in an MHC-unrestricted manner, display characteristics of effector activity and stemness without exhaustion and are nearly universally observed in human gynecol...

Full description

Saved in:
Bibliographic Details
Published in:Life (Basel, Switzerland) Switzerland), 2024-02, Vol.14 (3), p.325
Main Authors: Conejo-Garcia, Jose R, Anadon, Carmen M, Lopez-Bailon, Luis U, Chaurio, Ricardo A
Format: Article
Language:English
Subjects:
Antibodies
Anticancer properties
Antigens
Antitumor agents
butyrophilin
Cancer
Cancer immunotherapy
Care and treatment
Cell therapy
Cells
Cellular therapy
chimeric antigen receptor
Chimeric antigen receptors
Clinical trials
Cytokines
Cytotoxicity
Effector cells
Endometrial cancer
Genital cancer
Health aspects
Immune checkpoint inhibitors
Immunotherapy
Ligands
Lymphocytes
Lymphocytes T
Major histocompatibility complex
Malignancy
Oncology
Oncology, Experimental
Ovarian cancer
Reproductive system
Review
T cell
T cells
Tumor cells
tumor immunology
Tumors
γδ T cell
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Immuno-oncology has traditionally focused on conventional MHC-restricted αβ T cells. Yet, unconventional γδ T cells, which kill tumor cells in an MHC-unrestricted manner, display characteristics of effector activity and stemness without exhaustion and are nearly universally observed in human gynecologic malignancies, correlating with improved outcomes. These cells do not have a clear counterpart in mice but are also found in the healthy female reproductive tract. Interventions that modulate their in vivo activity, or cellular therapies utilizing γδ T cells as an allogeneic, "off-the-shelf" platform (e.g., for chimeric antigen receptor expression) hold significant potential against challenging tumors like ovarian cancer, which has been stubbornly resistant to the immune checkpoint inhibitors that change the landscape of other human tumors. Here, we discuss recent discoveries on the specific populations of γδ T cells that infiltrate human gynecologic cancers, their anti-tumor activity, and the prospect of redirecting their effector function against tumor cells to develop a new generation of immunotherapies that extends beyond the traditional αβ T cell-centric view of the field.
ISSN:2075-1729
2075-1729
DOI:10.3390/life14030325